CRA’s Rare Disease Spotlight team is excited to present Project LEOPARD, an ongoing assessment of the long-term evolution and outlook for patient access in rare disease. In this first installment, Cécile Matthews and Bhavesh Patel explore what we can expect for patient access in established, or competitive, rare diseases, and how life sciences companies can successfully navigate the future environment for this category of rare disease. Learn more about Project LEOPARD and subscribe to our rare disease insights.
Impact of CT outcomes on time to market and list price of orphan medicines in France
More innovative medicines have a shorter assessment time by the CT ASMR rating achieved vs. average time from EMA approval to outcome of CT assessment Key...